anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To prevent the deformation of a metallic base body at the time of firing ceramics and to improve the density and strength of the ceramics by enhancing the bioactivity of the ceramics and attaining the lower-temp. firing of the material. CONSTITUTION:A bioactive ceramic material which has a non-calcium phosphate type compsn. consisting essentially of at least one kind of an alkaline earth metal oxide or alkaline metal oxide and SiO2 and can form HAP in an aq. soln. contg. P ions and Ca ions is used as the ceramic material of the bioimplant formed by laminating a ceramic layer on the metallic base body. In addition, the bioactive ceramic power is formed as fine powder having &gt;=10m&lt;2&gt;/g BET value. As a result, the ceramic layer having the properties of &lt;=1200 deg.C firing temp. and &gt;=30MPa peeling strength is obtd.
Abstract of the Disclosure A dialkyl quaternary ammonium compound fall-ing within the formula   An-wherein R1 and R2 are the same or different straight chain alkyl radicals CnH2n+1 wherein n is predominant-ly at least 12, and particularly where n equals predomi-nantly 12-16, unexpectedly prevents Ext. D &amp; C Violet No.  2 dye from staining skin while providing better deposition of the Ext. D &amp; C Violet No. 2 onto human hair and wool to decrease or eliminate hair and wool yellowing.  These fatty radicals R1 and R2 are gener-ally derived from coconut oil, lauric acid, myristic acid, or palmitic acid and An- is any anion, parti-cularly the halogen ions and particularly the chloride ion.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a recombinant poxvirus-calicivirus such as RHDV and product derived from the recombinant virus.  &lt;P&gt;SOLUTION: The invention provides an attenuated recombinant virus containing a DNA encoding a calicivirus antigen such as an RHDV antigen, e.g., a capsid gene, and a method and a composition using the virus, expression product from the virus and an antibody generated from the virus or the expression product. The recombinant virus may be an NYVAC or ALVAC recombinant virus. The recombinant virus and gene product therefrom and antibody generated by the virus and gene product have several preventive, therapeutic and diagnostic uses. The DNA from the virus can be used for probes or for primers.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To provide a method for producing an UCN-01, capable of simply and efficiently producing the UCN-01 having an anti-tumor action and an anti- bacterial action by acidifying a solution containing an UCN-02. SOLUTION: This method for producing the UCN-01 of formula II comprises acidifying a solution containing UCN-02 of formula I to isomerize the UCN-02 into the UCN-01 and then recovering the UCN-01 from the solution. The solution containing the UCN-02 includes a solution obtained by oxidizing staurosporine in a solution comprising dimethyl sulfoxide and an alkali aqueous solution. The isomerization reaction is carried out, for example, by adding water to the solution containing the UCN-02 to give a water concentration of &gt;=90%(V/V), and then acidifying the solution with hydrochloric acid to change into a solution of pH 2-2.5. The concentration of the UCN-02 in the reaction solution is preferably 5-10 g/L. When the UCN-01 is contained in the reaction solution, the total concentration of the UCN-01 and the UCN-02 is preferably adjusted to the above concentration.  After the reaction is finished, the reaction solution is adjusted to pH 7 or higher to deposit the UCN-01.
The invention discloses a traditional Chinese medicine for treating anemia, which comprises the following raw materials in part by weight: 5 to 15 parts of Chinese angelica, 8 to 15 parts of dried orange peel, 3 to 10 parts of immature bitter orange, 5 to 10 parts of hawthorn fruit, 10 to 15 parts of chicken&#39;s gizzardskin, 5 to 10 parts of malt, 5 to 1t parts of astragalus, 5 to 15 parts of Codonopsis pilosula, 8 to 15 parts of white paeony root, 10 to 15 parts of rehmanniae vaporata, 5 to 10 parts of longan, 10 to 20 parts of suberect spatholobus sem, 3 to 10 parts of liquoric root, 5 to 15 parts of large head atractylodes rhizome, 10 to 30 parts of fructus ligustri lucidi and 10 to 15 parts of donkey-hide gelatin. The raw material components of the formula are mixed and decocted for three times and decocted for 30 to 50 minutes each time. The decoction is taken by three times, namely one time in the morning, one time at night, and one time in the morning of next day. 10 medicines form a treatment period. And cold and spicy foods are prohibited when the medicine is taken. The medicine is pure traditional Chinese decoction and has the effects of tonifying qi of middle-jiao energy, tonifying spleen, soothing liver, regulating qi, promoting digestion, appetizing, cooling blood, stop bleeding, clearing liver, clearing away heat, regulating kidney, promoting generation of body fluid, tonifying Qi and promoting blood generation. The medicine is a pure traditional Chinese medicine, prevents side effect after being taken and is good in treatment effect and quick in effectiveness.
CK2 is an anti-apoptotic protein found excessively activated in numerous tumours. With this work we show that CK2 inhibition dramatically influences neuroblastoma growth both in vitro and in vivo. In particular, we describe the identification of CK2-TN03, a CK2 inhibitor that has shown in cellular assays greater efficacy than silmitasertib, the only CK2 inhibitor for clinical use, currently designated as an &#34;orphan drug&#34; for the treatment of cholangiocarcinoma and in clinical trials for medulloblastoma. Our CK2-TN03 inhibitor works by suppressing the activity of the survivin protein, which is amplified in all high-ris k neuroblastomas. The functionality of survivin is directly reduced through the inhibition of its activating phosphorylation by CK2, whereas CK2 also regulates it indirectly, reducing its RNA and protein levels, altering the mdm2 /p53 balance through BRD4 /NMYC. As a result, neuroblastoma cells stall in mitosis for a long time before entering apoptosis. Furthermore, it is important to note that CK2-TN03 does not act on cells that are not actively reproducing and significantly reduces tumour growth in mouse xenografts.
A vision screening system for testing the vision of a patient is described herein. The vision screening system may include a vision screening device configured to perform a number of vision screening tests. For example, the system may be configured to determine or generate a graphical representation for display to the patient, via the vision screening device, to evaluate the health of the patient&#39;s vision and/or detect abnormal vision behavior. The system may be configured to evaluate image/video data recorded by the vision screening device to determine measurements associated with the patient during the vision screening. The system may be configured to analyze the measurements to generate a diagnosis recommendation associated with the vision of the patient. The system may also be configured to display the recommendation and/or the measurements, along with additional screening data, to a tester conducting the vision test.
PURPOSE:To obtain the titled gold alloy consisting of prescribed percentages of Au, Ag, Pd, Cu and In, assuming a gold color comparable to that of a high karat gold alloy in spite of the low Au content, and having high corrosion resistance. CONSTITUTION:This low karat gold alloy for casting assuming a gold color consists of, by weight, 30-50% Au, 5-35% Ag, 5-15% Pd, 10-20% Cu and 10- 18% In. The physical properties of the alloy can be further improved by adding one or more among &lt;=0.1% Ir, &lt;=2% Pt and 5% Zn to the alloy. The corrosion resistance and gold color of the gold alloy are comparable to those of a 14k. gold alloy, and this alloy can be widely used as a gold alloy for casting an inlay, a crown, a bridge, etc. for dental use, accessories, etc.
The present invention relates to the application of crust oligosaccharide sulfuric ester and/or chitosan sulfuric ester to the preparation of a medicine for reducing blood sugar. The compounds of the medicine for preventing and treating diabetes comprise crust oligosaccharide sulfuric ester (CSA) and/or chitosan sulfuric ester (CSB). the typical structures of the two compounds are shown by the right formula, wherein the n is polymerization degree which is from 3 to 600; the R1 is SO3Na or H; the R2 is SO3Na or H or Ac; both the R1 and the R2 are H except for Ac. the content of the active group, namely sulfuric ester base (OSO3&lt;-&gt;) of the compound is from 40.73 to 42.21%, wherein the molecular weight of the crust oligosaccharide sulfuric ester (CSA) in a yellowish cotton state is from 1 to 6KD; the molecular weight of the chitosan sulfuric ester (CSB) in a yellowish cotton stage is from 30 to 100KD. The medicine compound displays activity on the aspects of resisting blood sugar, adjusting blood fat, reinforcing immunity, resisting blood coagulation, etc., and is influenced by the sulfuric ester base, which is an active group and the molecular weight thereof. The preparation method belongs to homogeneous reaction. The present invention has the advantages of simpleness, low operation cost, little pollution and high raw material utilization rate.
PURPOSE:A composition, obtained by incorporating a lipophilic sucrose ester of a fatty acid with starch ester of a fatty acid and an oily component, and capable of being a cosmetic having improved usability and good stability for a long term. CONSTITUTION:An oily gel composition obtained by incorporating a lipophilic sucrose ester of a fatty acid with a starch ester of a fatty acid and an oily component. The content of both esters is 1-40wt%, and the content of the oily component is 99-60wt%. The mixing ratio between both esters is 1/39pts.wt. starch ester of the fatty acid and 1pt.wt. lipophilic sucrose ester of the fatty acid. Preferably, a sucrose ester of the fatty acid, having &gt;=12 carbon atoms, and containing &lt;=10wt% monoester is used as the sucrose ester of the fatty acid, and an ester of a saturated fatty acid of a starch hydrolyzate having 10-50 average polymerization degree is used as the starch ester of the fatty acid.
The present invention relates to medicinal powder for treating hemorrhoids, which belongs to the field of Chinese patent medicines. The medicinal powder for treating hemorrhoids uses 18 to 23 wt% of scolopendra and 77 to 82 wt% of chicken&#39;s large intestine as raw materials. The medicinal powder for treating hemorrhoids is prepared by that the scolopendra is put into the washed chicken&#39;s large intestine, and the scolopendra and the chicken&#39;s large intestine are fried in sesame oil by slow fire and ground into powder. The medicinal powder for treating hemorrhoids is taken after being mixed with hot liquor, once a day, 3 to 6 grams each time, and 7 days form a treatment course. The total effective rate is 95%. Proved in clinic, the medicine has the advantages of safety and light side effect and safety.
PURPOSE:To easily obtain a cosmetic having high masking power and excellent covering effect, effective even at a low content of coloring pigment and giving excellent feeling to the skin such as spreadability and adhesivity to the skin, smooth feeling, etc., by using plate red iron oxide as an active component. CONSTITUTION:Plate red iron oxide is compounded to a cosmetic. The amount of the oxide depends upon the type of the cosmetic, however, it is within the range of 0.1-60wt%. The plate red iron oxide used in the present cosmetic has an average particle diameter of 0.05-1mu along the direction of plane, a thickness of 0.01-0.2mu and an aspect ratio (plate diameter/thickness) of &gt;=2.0. More preferably, the ratio of particle diameter at the 1st quartile to the 3rd quartile in the cumulative distribution curve of particle diameter is 0.67-1.50 and that of the 1st decile to the 9th decile is 0.5-2.0. The plate red iron oxide can be produced e.g. from an aqueous slurry containing 3 components comprising a ferric salt, tartaric acid and an alkaline compound.
Apparatus and associated methods relate to the determination of local environmental air quality by processing data from a local device sensing a user&#39;s respiration-vocalization. In an illustrative example, respiration-vocalization for a CPAP user may be sensed by an airflow and/or air pressure sensor. Respiratory disturbance events, such as coughing, for example, may be detected. The sensed events, converted to respiration-vocalization data, may be collected to estimate the environmental air quality and/or particle density around the user. Some examples may estimate specific allergen concentrations by correlating user respiration-vocalization data with the respiration-vocalization data from users/patients with known airborne particle sensitivities. In some embodiments, regional environmental air quality data may be compared with respiration-vocalization data to produce local environmental air quality results. Various results may advantageously indicate specific allergen conditions in an area based on monitoring of a population of users of CPAP machines or other devices in widespread use.
PROBLEM TO BE SOLVED: To obtain the subject regulator capable of preventing the viscosity of a water-based manicure from changing with time and also capable of improving the dispersion stability of other formulating ingredients such as a pigment. SOLUTION: This viscosity regulator is a gel composition obtained by homogeneously mutually dispersing and mixing (A) a bentonite-based clay mineral (e.g. synthetic smectite), (B) a peptization-promotive auxiliary (e.g. ethylene glycol diethyl ether), and (C) water to effect gelation. The proportion of the components A, B and C in the gel composition is as follows: A:B:C=1:(1-100):(5-1000). It is preferable that the viscosity of the gel composition be &gt;=10000cps. Besides, the gel composition is pref. incorporated with a thixotropic substance. Use of the gel composition as a viscosity regulator for water-based manicure gives such a water-based manicure as to be excellent in homogeneity and dispersion stability of the whole system, extremely good in coatability on the nails, and also excellent in the water resistance and adhesiveness to the nails of the film therefrom after dried.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a food product for ameliorating constipation, derived from a natural product, and having a high constipation-ameliorating activities by using lactic acid bacteria, especially deactivated lactic acid bacteria.  &lt;P&gt;SOLUTION: This food product for ameliorating the constipation contains killed lactic acid bacteria (e.g. Enterococcus faecalis). The constipation-ameliorating food product containing the killed lactic acid bacteria, at least one of a vegetable fiber, an oligosaccharide and aloe, and a pasted product of a kale (Brussicaoleracea L var acephala) is cited as an example. The use of the killed lactic acid bacteria enables the food product containing the kale added with the lactic acid bacteria to be produced. The obtained food product is excellently safe and has excellent constipation-ameliorating activities, properties of which are superior ones.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To enable work management in a dispensing pharmacy as using a picking inspection system enabling job tracking from the viewpoint of dispensing error prevention.  &lt;P&gt;SOLUTION: A worker in charge inputs contents described on a received prescription into a computer 1 (S2), and another person (worker) in charge checks the input data against the contents of the prescription (prescription input check) (S3). A picking job is then performed (S4). A worker such as a pharmacist in charge checks the picking to reveal whether picked medicine names and amounts are correct or not (S5). Administration guidance is then given (S6). The inputs can be either an information terminal such as a handy terminal 5 or the computer 1. Job content and input time data, which are stored as work history data for every input, are used in work management in a dispensing pharmacy.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A novel method of treating Kaposi&#39;s sarcoma (KS) in patients, by administration of an effective amount of VEGF antagonist/s. VEGF antagonists are capable of inhibiting the growth of KS cells in culture by inhibiting the production of VEGF, or by interfering with the binding of VEGF to its cognate receptors or interfere with the biological effects of VEGF. The VEGF antagonist may be administered to KS patients topically, orally, or parentally. Other VEGF antagonist such as VEGF antibodies, VEGF receptor antibodies, soluble forms of VEGF receptors that bind VEGF away from the cells, or agents that inhibit the signal of VEGF into the cell such as protein kinase inhibitors etc. can also be used The novel antisense oligonucleotides (Veglin-1 and Veglin-3) may also be used to inhibit VEGF and thus new blood vessel formation in diseases such as tumors, proliferative retinopathy, or collagen vascular diseases such as rheumatoid arthritis, and skin diseases such as pemphigus and psoriasis. The KS cell lines also allow-the screening of other VEGF inhibitors.
A method for utilizing robotic surgical data for providing surgical training is disclosed. The method includes collecting, by a computing device, data related to a surgical procedure from one or more components of a computer-assisted surgical system. At least one of the one or more components is a robotically controlled surgical device. A graphical depiction representative of the surgical procedure is generated based on the collected data from the one or more components of the computer-assisted surgical system and one or more images providing a visual depiction of a patient&#39;s anatomy. A graphical user interface is output to a display device. The graphical user interface includes the graphical depiction of the surgical procedure and the collected data from the one or more components of the computer-assisted surgical system, to provide surgical training.
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual&#39;s eye to which the material is administered.  The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.
A resin/drug compound is prepared by contacting &#34;Amberlite&#34; (Registered Trade Mark) IR-120 (in the hydrogen form) with an aqueous solution of dihydrocodeinone bitartrate with stirring. The compound contains about 26,22% by weight of the drug.  The resin/drug compound is dispersed in water in the presence of air and using a colloidal thixotropic suspending agent.  Compositions with specified therapeutic agents are described.ALSO:Thixotropic medicines comprise a stable aqueous suspension of a water-insoluble drug and air in a medium including a suspension of a potassium salt of a sulphuric ester of a high molecular weight polysaccharide obtained by water extraction of the seaweed Furcellaria fastigiata as thixotropic agent.  The compositions may be prepared using a conventional double chambered dispersator in which the thixotropic agent is blended into the aqueous medium by mechanical and hydraulic shearing action which also aerates the composition, the water-insoluble drug being added subsequently.  A specific example relates to a suspension of dihydrocodeinone &#34;resinate&#34; (see Group IV (a)), other specified drugs which may be used are: antibiotics, e.g. procaine penicillin, chloro-mycetin, erythromycin stearate; gastro-intestinal agents, e.g. aluminium hydroxide and phosphate gels, polyamine methylene resins, magnesium trisilicate, kaolin and bismuth subcarbonate; diuretics and cardiovascular agents, e.g. theophylline; vasodilators, e.g. quinidine; steroids, e.g. progesterone and testosterone and, particularly, sulpha-drugs, e.g. sulphamethazine, sulphadiazine, sulphaethyl-thiadiazole, sulphaguanidine and sulphamerazine.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a substance usable for the prevention, treatment and diagnosis of cancers (e.g. prostate cancer) and a method for improving the prevention, treatment and diagnosis of cancers (e.g. prostate cancer and mammary cancer).  &lt;P&gt;SOLUTION: The inventors have found a series of proteins containing some proteins to use a +2 reading frame and formed by splicing in the env region of HERV-K genome. These proteins show activity typical of transcriptional regulators and have oncogenic potential. These proteins are usable in the diagnosis and treatment of cancers and are drug targets e.g. for adjuvant therapy.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an image processor and an image processing method searching an affected portion from all images based on diagnosis information and selecting an image or an image set including the lesion portion.  &lt;P&gt;SOLUTION: In a step S1, imaging data are input in an image input part 1. In a step S2, diagnosis results using the imaging data by a doctor are input in a diagnosis information input part 2 as diagnosis information. In a step S3, key words input in the diagnosis information input part 2 or a diagnosis information analysis part 3 are searched from a keyword table 7. In a step S4, a parameter determination part 5 selects initial value parameters to be used in an image search part 4 are selected from the initial value table 8 based on the input keywords. In steps S5 and S6, the image search part 4 determines the appropriateness of the parameters based on the area and the connectivity of the lesion area by applying the selected parameters to the input image and extracts the lesion area using a general computer diagnosis supporting technology.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
NEW MATERIAL:A bonded material having the following properties. Appearance, white, pale yellow or yellow powder; solubility, easily soluble in water. EXAMPLE:Bonded ascorbic acid and geraniin of formula. USE:An agent suppressing lipid peroxide level in living body. Utilizable in the fields of medicine, food and cosmetic, etc. It has excellent safety and stability. PREPARATION:For example, 1-2mol of a tannin such as geraniin extracted from Geranium nepalense and 2-10mol of ascorbic acid are dissolved or dispersed in a mixture of water and alcohol and made to react with each other by heating at &lt;=40 deg.C under stirring. The reaction mixture is treated by column chromatography to separate the objective material.